On behalf of Beijing Boren Hospital, Director Jing PAN in the Department of Hematology in our hospital delivered a speech at the 23rd annual conference of the European Hematology Association (EHA) held in Stockholm, Sweden, and reported the results of the clinical study on humanized CD22-CART cell therapy in 15 children with refractory/relapsed B-cell acute lymphoblastic leukemia (B-ALL). The participating experts paid great attention to this study , which was widely reported by domestic and overseas media after the conference.